Sun Pharma down 2%, stock hits over 5-month low
BSE moved lower.
· Business Standard Mkts
Thus far in the calendar year 2026, Sun Pharma outperformed the market and remained flat, as compared to a 14.7% decline in the BSE Sensex.
The analysis
BSE reported movement of 2% and 14.7%. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -1.4% on the day at ₹1,746.40, and has returned -11.1% over three months. It sits 13% below its 52-week high. The pharma & healthcare sector has moved -3.0% over the same period, so Sun Pharmaceutical is running 8.1 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- With BSE involved, this carries a regulatory dimension that can outlast the immediate market reaction.
Market context
- The company directly in focus is SUNPHARMA.
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Sun Pharma board approves plan to raise up to ₹10,000 crore via NCDs
This small-cap stock surged 75% since IPO price but ICICI Securities sets target below CMP; what should shareholders do?
Taking Stock: Market fails to hold on to day#39;s gains, ends marginally higher
Sensex, Nifty muted a day after sharp rally, IT stocks extend gains. What lies ahead for Dalal Street?
Stock Market Live Updates: Sensex Volatile, Nifty 50 Slips In Red; Tata Elxsi Rallies 8% After Q2 Results